- Home
- INVE vs HOWL Comparison
INVE vs HOWL Comparison
Compare INVE & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVE
- HOWL
- Stock Information
- Founded
- INVE 1990
- HOWL 2017
- Country
- INVE United States
- HOWL United States
- Employees
- INVE N/A
- HOWL N/A
- Industry
- INVE Computer peripheral equipment
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- INVE Technology
- HOWL Health Care
- Exchange
- INVE Nasdaq
- HOWL Nasdaq
- Market Cap
- INVE 74.2M
- HOWL 53.4M
- IPO Year
- INVE 1997
- HOWL 2021
- Fundamental
- Price
- INVE $3.26
- HOWL $1.10
- Analyst Decision
- INVE Strong Buy
- HOWL Strong Buy
- Analyst Count
- INVE 3
- HOWL 3
- Target Price
- INVE $6.50
- HOWL $8.33
- AVG Volume (30 Days)
- INVE 52.7K
- HOWL 648.5K
- Earning Date
- INVE 08-07-2025
- HOWL 08-07-2025
- Dividend Yield
- INVE N/A
- HOWL N/A
- EPS Growth
- INVE N/A
- HOWL N/A
- EPS
- INVE 3.12
- HOWL N/A
- Revenue
- INVE $25,239,000.00
- HOWL $1,143,000.00
- Revenue This Year
- INVE N/A
- HOWL N/A
- Revenue Next Year
- INVE $9.00
- HOWL N/A
- P/E Ratio
- INVE $1.05
- HOWL N/A
- Revenue Growth
- INVE N/A
- HOWL N/A
- 52 Week Low
- INVE $2.86
- HOWL $0.60
- 52 Week High
- INVE $4.35
- HOWL $4.18
- Technical
- Relative Strength Index (RSI)
- INVE 48.50
- HOWL 46.17
- Support Level
- INVE $3.10
- HOWL $1.18
- Resistance Level
- INVE $3.25
- HOWL $1.30
- Average True Range (ATR)
- INVE 0.11
- HOWL 0.12
- MACD
- INVE 0.00
- HOWL -0.03
- Stochastic Oscillator
- INVE 38.46
- HOWL 6.33
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.